CN1266679A - 基于乙氧化脂肪醚或乙氧化脂肪酯的毫微乳及其用途 - Google Patents
基于乙氧化脂肪醚或乙氧化脂肪酯的毫微乳及其用途 Download PDFInfo
- Publication number
- CN1266679A CN1266679A CN99127471A CN99127471A CN1266679A CN 1266679 A CN1266679 A CN 1266679A CN 99127471 A CN99127471 A CN 99127471A CN 99127471 A CN99127471 A CN 99127471A CN 1266679 A CN1266679 A CN 1266679A
- Authority
- CN
- China
- Prior art keywords
- millimicro
- breast
- oil
- aforementioned
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 title claims description 32
- 239000007908 nanoemulsion Substances 0.000 title abstract 3
- 150000002194 fatty esters Chemical class 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 239000012071 phase Substances 0.000 claims abstract description 28
- 239000004094 surface-active agent Substances 0.000 claims abstract description 26
- 210000004209 hair Anatomy 0.000 claims abstract description 11
- 210000004761 scalp Anatomy 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 9
- 239000007787 solid Substances 0.000 claims abstract description 8
- 239000008346 aqueous phase Substances 0.000 claims abstract description 4
- 210000000481 breast Anatomy 0.000 claims description 83
- 239000003921 oil Substances 0.000 claims description 57
- -1 ethoxyquin fatty ester Chemical class 0.000 claims description 24
- 239000004258 Ethoxyquin Substances 0.000 claims description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 18
- 229940093500 ethoxyquin Drugs 0.000 claims description 18
- 235000019285 ethoxyquin Nutrition 0.000 claims description 18
- 125000001931 aliphatic group Chemical group 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 150000002148 esters Chemical class 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 11
- HOWGUJZVBDQJKV-UHFFFAOYSA-N docosane Chemical compound CCCCCCCCCCCCCCCCCCCCCC HOWGUJZVBDQJKV-UHFFFAOYSA-N 0.000 claims description 10
- DECIPOUIJURFOJ-UHFFFAOYSA-N ethoxyquin Chemical group N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 claims description 9
- 230000003796 beauty Effects 0.000 claims description 8
- 230000000474 nursing effect Effects 0.000 claims description 7
- 150000001447 alkali salts Chemical class 0.000 claims description 6
- 239000004530 micro-emulsion Substances 0.000 claims description 6
- 210000004877 mucosa Anatomy 0.000 claims description 6
- RZJRJXONCZWCBN-UHFFFAOYSA-N octadecane Chemical compound CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 5
- 150000004665 fatty acids Chemical group 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 229920002545 silicone oil Polymers 0.000 claims description 5
- 239000002537 cosmetic Substances 0.000 claims description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 3
- 206010013786 Dry skin Diseases 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 125000000129 anionic group Chemical group 0.000 claims description 3
- 125000002091 cationic group Chemical group 0.000 claims description 3
- 230000037336 dry skin Effects 0.000 claims description 3
- 238000000265 homogenisation Methods 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- 235000010446 mineral oil Nutrition 0.000 claims description 3
- 229940038384 octadecane Drugs 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 159000000000 sodium salts Chemical class 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 229940093541 dicetylphosphate Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 238000010008 shearing Methods 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 239000004519 grease Substances 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 210000001508 eye Anatomy 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 abstract description 2
- 150000002195 fatty ethers Chemical class 0.000 abstract 1
- 210000004400 mucous membrane Anatomy 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 6
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- WODOUQLMOIMKAL-FJSYBICCSA-L disodium;(2s)-2-(octadecanoylamino)pentanedioate Chemical compound [Na+].[Na+].CCCCCCCCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CCC([O-])=O WODOUQLMOIMKAL-FJSYBICCSA-L 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical group CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000003760 tallow Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 244000025272 Persea americana Species 0.000 description 2
- 235000008673 Persea americana Nutrition 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 229960000735 docosanol Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl tetradecanoate Chemical class CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000047703 Nonion Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000008931 Tadenan Substances 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- 230000001384 anti-glaucoma Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- FLNKWZNWHZDGRT-UHFFFAOYSA-N azane;dihydrochloride Chemical compound [NH4+].[NH4+].[Cl-].[Cl-] FLNKWZNWHZDGRT-UHFFFAOYSA-N 0.000 description 1
- 229940084850 beheneth-10 Drugs 0.000 description 1
- 229940091509 beheneth-20 Drugs 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- YSJGOMATDFSEED-UHFFFAOYSA-M behentrimonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCCCCCC[N+](C)(C)C YSJGOMATDFSEED-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000004064 cosurfactant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical group CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 229940098760 steareth-2 Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229940014903 tadenan Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K23/00—Use of substances as emulsifying, wetting, dispersing, or foam-producing agents
- C09K23/34—Higher-molecular-weight carboxylic acid esters
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K23/00—Use of substances as emulsifying, wetting, dispersing, or foam-producing agents
- C09K23/42—Ethers, e.g. polyglycol ethers of alcohols or phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/21—Emulsions characterized by droplet sizes below 1 micron
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/26—Optical properties
- A61K2800/262—Transparent; Translucent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/14—Preparations for removing make-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Materials Engineering (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Dispersion Chemistry (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及具有小于100nm平均大小的油珠滴的毫微乳,它包括在低于或等于45℃下为固体的选自乙氧化脂肪醚或乙氧化脂肪酯的表面活性剂和至少一种分子量大于400的油,并且油相与表面活性剂的量的比率(重量)在2至10范围内。本发明也涉及本发明毫微乳在美容和皮肤科领域的用途,特别是使皮肤和/或粘膜增加水分以及处理头发的用途,并且在眼科领域作为处理眼睛的眼部洗剂。
Description
本发明涉及基于在低于或等于45℃下为固体的选自乙氧化脂肪醚或乙氧化脂肪酯的表面活性剂和基于至少一种分子量大于400的油、且油相重量与表面活性剂的重量的比率在2至10范围内的毫微乳。
本发明也涉及制备该所述毫微乳的方法和涉及它在美容、皮肤科药物和/或眼科药物领域的用途。该毫微乳在贮存时是稳定的，并且可包括大量的油而同时保持良好透明度和具有良好的美容性质。
毫微乳为水包油乳剂，它的油珠滴具有非常精细的颗粒大小。即数均大小小于100nm。它们通常在表面活性剂存在下通过油相在水相中机械碎裂过程来制备。在毫微乳情况下，特别地通过经过高压匀浆器至少一次来得到很小体积的油珠滴。该珠滴使它们本身具有了美容的有利性质，这些性质使它们区别于常规乳剂：它们是透明的并且呈现新的结构。它们也能更有效地运载活性成分。
透明微乳在本领域是已知的。与毫微乳相反，微乳严格地讲不是乳剂；它们是由通常是很短链的油(例如己烷或癸烷)溶胀的透明的胶束溶液，并且借助有效量的表面活性剂和形成胶束的辅助表面活性剂联合存在而溶解。所溶胀的胶束的体积是很小的，这归因于它们能溶解小量的油。如同毫微乳一样，这些胶束很小的体积是它们透明性的原因。然而，与毫微乳相反，微乳通过除了简单的磁力搅拌以外不提供机械能下而使这些成分混合来自然形成。微乳的主要缺点是使用高比例的表面活性剂，这导致了不可耐受性并在应用到皮肤上时引起粘的感觉。此外，它们的制剂范围通常很窄并且它们的温度稳定性是很有限的。
另外，在本领域已知的毫微乳包括由磷脂、水和油组成的两亲性脂相。这些乳剂在常规贮存温度下即0和45℃之间呈现出对于贮存来说不稳定的缺点。它们导致黄色的组合物并且在贮存几天后产生发生的酸败的味道。
通过由亲水性表面活性剂和亲脂性表面活性剂合并得到的层状的液晶盖覆层来稳定的毫微乳也是已知的。然而，这些结合对于制备是成问题。此外，所得到的毫微乳呈现出蜡状的和形成薄膜的感觉，这种感觉对于使用者来说是非常不舒服的。
此外，文献EP-A-728,460公开了基于流体的非离子两亲性脂质的毫微乳。然而，这些毫微乳在应用于皮肤时具有粘着作用的缺点。
因此，对于毫微乳来说仍然需要不具有先有技术的那些缺点也不具有微乳的缺点的毫微乳。
Applicant公司现在意外地发现了使用在低于或等于45℃下为固体的选自乙氧化脂肪醚和乙氧化脂肪酯的表面活性剂和至少一种分子量大于400(＝每摩尔400克)的油使得可能得到呈现出已知毫微乳的优点而无它们的缺点的新的毫微乳。
本发明的论题为包括了分散在水相中的油相、并且具有小于100nm的均数大小的油珠滴的毫微乳，其特征在于它包括在低于或等于45℃下为固体的选自乙氧化脂肪醚和乙氧化脂肪酯的表面活性剂和至少一种分子量大于400的油，并且其中油相与表面活性剂的重量比率在2至10范围内。
本发明的毫微乳对于带蓝色外观通常具有透明性。它们的透明性通过在600nm下在10至90％范围的传导系数来测量，或者也可通过60至600 NTU范围并且优选70至300 NTU的浊度来测量，其浊度用Hach Model 2100P便携式浊度计来测量。
本发明毫微乳的油珠滴具有小于100nm的均数大小，并且优选为20至75nm范围并且更优选为从40至60nm。该珠滴在大小的减少使促进所述活性成分渗透进入皮肤的表层成为可能(载体效应)。
本发明毫微乳中可以使用在低于或等于45℃下为固体的表面活性剂为乙氧化脂肪醚或乙氧化脂肪酯，这意味着本发明的毫微乳仅包括选自这些醚或酯的表面活性剂并且除了乙氧化脂肪醚和乙氧化脂肪酯以外没有任何表面活性剂。
在低于或等于45℃下为固体的在本发明毫微乳中能够用作表面活性剂的乙氧化脂肪醚为由1至100个环氧乙烷单位的和至少一个具有16至22个碳原子的脂肪醇链所形成的醚。这些醚的脂肪链特别选自二十二醇、二十烷醇、十八烷醇或十六烷醇单位和它们的混合物如十八醇十六醇(cetearyl)混合物。作为乙氧化脂肪醚的实例可以提及包括5、10、20和30个环氧乙烷单位的二十二醇醚(CTFA命名为：Beheneth-5、Beheneth-10、Beheneth-20、Beheneth-30)如由Nikko公司以Nikko BB5、BB10、BB20和BB30的名称销售的产品和包括2个环氧乙烷单位的十八烷醇醚(CTFA命名为：Steareth-2)如由ICI公司以Brij 72的名称销售的产品。
在低于或等于45℃下为固体的在本发明毫微乳中能够用作表面活性剂的乙氧化脂肪酯为由1至100个环氧乙烷单位和至少一个具有16至22个碳原子的脂肪酸链所形成的酯。这些酯的脂肪链特别选自硬脂酸酯、二十二烷酸酯、二十烷酸酯或棕榈酸酯单位和它们的混合物。作为乙氧化脂肪酯的实例可以提及包括40个环氧乙烷单位的硬脂酸酯如由ICI公司以Myrj 52名称(CTFA命名为：PEG-40硬脂酸酯)销售的产品和包括8个环氧乙烷单位的二十二烷酸酯(CTFA命名为：PEG-8二十二烷酸酯)如由Gattefosse公司以CompritolHD5 ATO名称销售的产品。
本发明毫微乳中的表面活性剂的量相对于该毫微乳的总重量计在例如0.2至15％(重量比)的范围并且优选为1至8％(重量比)的范围。
所述油相相对于表面活性剂的量的重量比率在2至10，并且优选为3至6的范围内。术语“油相的量”此处理解为意指在不包括所述表面活性剂的量情况下该相组分的总量。
本发明毫微乳包括至少一种分子量大于400的油。该分子量大于400的油可选自动物或植物来源的油、矿物油、合成油和硅油和它们的混合物。作为该类型的油可以提及例如棕榈酸异十六烷基酯、硬脂酸异十六烷基酯、鳄梨油或霍霍巴油。
此外，该油相能任选包括其它的油，尤其是具有分子量小于400的油。这些油也选自动物或植物来源的油、矿物油、合成油和硅油。作为分子量小于400的油可以提及例如异十二烷、异十六烷、挥发性硅油、十四烷酸异丙基酯、棕榈酸异丙基酯或C11-C13异构烷烃。
该油相也可包括除了以上所表明的油以外的脂肪物质，例如脂肪醇如十八烷醇、十六烷醇和二十二烷醇、脂肪酸如硬脂酸、棕榈酸和二十二烷酸、氟代类型的油、蜡、树胶和它们的混合物。
本发明毫微乳包括一定量的油相优选为相对于毫微乳总重量计2至40％范围并且优选5至30％(重量)，具有分子量大于400的油的比例优选为至少40％(重量)的油相。
按照本发明的具体实施方案，本发明毫微乳另外包括一种或多种离子化两亲性脂质。
可用于本发明毫微乳的离子化两亲性脂质优选地选自阴离子两亲性类脂、阳离子两亲性类脂和烷基磺基衍生物。
所述阴离子两亲性类脂可更具体地选自：-联十六烷基磷酸酯和联十四烷基磷酸酯的碱性盐；-胆固醇硫酸酯的碱性盐；-胆固醇磷酸酯的碱性盐；-脂氨基酸(lipoamino acid)和它们的盐如酰基谷氨酸的单-和双钠盐，如由Ajinomoto公司以Acylglutamate HS21名称销售的N-硬脂酰-L-谷氨酸二钠盐；-磷脂酸的钠盐；-磷脂。所述烷基磺酸衍生物可更具体地选自式(I)的烷基磺酸衍生物：
其中R代表一个包括16至22个碳原子的烷基基团，特别为C16H33和C18H37基团，作为混合物或单独使用，并且M为碱金属如钠。
所述阳离子两亲性类脂能够更具体地选自季铵盐、脂肪胺和它们的盐。
例如所述季铵盐为：-具有以下通式(II)的那些季铵盐：
其中R1-R4基团为相同的或不同的，代表一个包括1至30个碳原子的线性的或分支的脂肪族基团或者芳族基团如芳基或烷基芳基。所述脂肪族基团可以包括杂原子如特别地为氧、氮、硫或卤素。该脂肪族基团例如选自烷基、烷氧基、多氧(C2-C6)链烯基、烷基酰氨基、(C12-C22)烷基酰氨基(C2-C6)烷基、(C12-C22)烷基乙酸酯或包括大约1至30个碳原子的羟基烷基基团；X为选自卤化物、磷酸根、乙酸根、乳酸根、(C2-C6)烷基硫酸根或者烷基-或烷基芳基磺酸根的阴离子。一方面，式(II)季铵盐优选为四烷基铵氯化物如二烷基二甲基铵氯化物或烷基三甲基铵氯化物，其中所述烷基基团包括大约12至22个碳原子，特别为二十二烷基三甲基铵氯化物、二-十八烷基二甲基铵氯化物、十六烷基三甲基铵氯化物和苄基二甲基十八烷基铵氯化物，或者另一方面，由Van Dyk公司以《Ceraphyl 70》名称而销售的十八烷酰氨基丙基二甲基(十四烷基乙酸酯)铵氯化物。-咪唑啉季铵盐，例如下式(III)的那些咪唑啉季铵盐：
其中R5代表包括8至30个碳原子的链烯基或烷基基团，例如衍生自动物脂脂肪酸的链烯基或烷基基团；R6代表氢原子、包括1至4个碳原子的烷基基团或者包括8至30个碳原子的链烯基或烷基基团；R7代表包括1至4个碳原子的烷基基团；R8代表氢原子或包括1至4个碳原子的烷基基团；并且X为选自卤化物、磷酸根、乙酸根、乳酸根、烷基硫酸根或者烷基-或烷基芳基磺酸根的阴离子。R5和R6优选地代表包括12至21个碳原子例如衍生于动物脂脂肪酸的链烯基或烷基基团的混合物，R7优选表示甲基基团和R8优选表示氢原子。例如像这样的产品为由Rewo公司以《Rewoquat W75》名称而销售。-式(IV)的季二铵盐：
其中R9表示包括大约16至30个碳原子的脂肪族基团；R10、R11、R12、R13和R14选自氢或包括1至4个碳原子的烷基基团；并且X为选自卤化物、乙酸根、磷酸根、硝酸根和甲基硫酸根的阴离子。
这样的季二铵盐特别包括丙烷动物脂二铵二氯化物。
按照本发明优选的实施方案，脂氨基酸用作离子两亲性类脂。
所述离子两亲性类脂能被导入该毫微乳的这个或另一个相中。当它们存在于本发明的毫微乳时，相对于该毫微乳的总重它们优选以从0.01至5％(重量)且更优选0.25至1％(重量)的浓度使用。
本发明乳剂可包括用于改善所述制剂透明性的添加剂。
这些添加剂优选地选自：-包括1至8个碳原子的低级醇，并且更优选2至6个碳原子的醇如乙醇；-二元醇类如甘油、丙二醇、1，3-丁二醇、二丙二醇、戊二醇、异戊二醇和包括4至16并优选8至12个环氧乙烷单位的聚乙二醇；-糖类如葡萄糖、果糖、麦芽糖、乳糖或蔗糖。
这些添加剂可作为混合物使用。当它们存在于本发明的毫微乳时，相对于该毫微乳的总重它们优选地以0.01至3％(重量)的浓度、并且相对于该毫微乳的总重优选地以5至20％(重量)的浓度使用。相对于该毫微乳的总重计醇和/或糖的量优选地以5至20％(重量)范围、并且相对于该毫微乳的总重计二元醇的量优选地以5至15％(重量)的浓度范围使用。
另外，如上所定义的醇的使用浓度大于或等于15％醇(重量)使得获得无防腐剂的乳剂成为可能。
以上所定义的毫微乳可用于其中这种类型的组合物是有用的任何领域。它们可构成特别用于局部使用的组合物，并且尤其是用于美容的或皮肤病的组合物。它们也可用作眼科用载体。另外，在药学领域中它们可构成口服、非肠道或透皮给药的药用组合物。
因此本发明的另一个论题为局部使用的组合物，其特征在于它包括如上所定义的毫微乳。
局部或药用用途的组合物包括生理上可接受的也就是说与皮肤、粘膜、头皮、眼睛和/或头发相容的载体。
本发明另一个论题为眼科用载体，其特征在于它包括如上所定义的毫微乳。
本发明另一个论题为药用组合物，其特征在于它包括如上所定义的毫微乳。
本发明的毫微乳可包括具有美容、皮肤用或眼科用活性的水溶性或脂溶性的活性成分。该脂溶性活性成分以乳剂的油珠滴形式存在，而水溶性的活性成分以乳剂的水相形式存在。作为活性成分的实例，可以提及的是维生素如维生素E和它们的衍生物，特别是它们的酯、前维生素如泛醇、湿润剂和防晒剂。
作为眼科用活性成分，可以提及的是例如抗青光眼药物如倍他洛尔、抗生素如阿昔洛韦、抗过敏药、抗炎药如异丁苯丙酸和它的盐、双氯芬酸和它的盐或吲哚美辛或抗病毒药物。
本发明毫微乳能以洗剂、浆液、霜剂、奶液或花露水的形式提供，并且可包括通常用于美容、皮肤科和眼科领域的辅助剂如凝胶剂、防腐剂、抗氧剂和香料。它们也能以特别应用于眼科使用的眼部洗剂形式来提供。
在所使用的胶凝剂中，可以提及的是纤维素衍生物、藻的衍生物、天然树胶和合成聚合物如羧乙烯基酸的聚合物和共聚物，例如那些由Goodrich公司以Carbopol名称销售的。
本发明的另一个论题为制备如上所定义的毫微乳的方法，该方法包括在10至80℃范围内、在伴随剧烈搅拌下使水相与油相混合，然后在优选6×107Pa至18×107Pa范围内的压力下使该混合物均化(高压均化作用)。该剪切优选为2×106s-1至5×108s-1的范围内，并且更优选为1×108s-1至3×106s-1(s-1表示秒-1)。
本发明毫微乳可用于例如护理、处理或化妆皮肤、脸和/或头皮。
因此本发明的另一个论题为如上所定义的毫微乳用于护理、处理和/或化妆皮肤、脸和/或头皮的美容用途。
此外，本发明毫微乳也可用于护理和/或处理头发。这使得得到油在头发上的沉积成为可能，该种沉积使头发更有光泽并且对于发型更耐久(more resistant to styling)而不是造成发型平直。这也使预处理以改善染色的效果或发型的持久的鬈曲成为可能。
因此本发明的另一个论题为如上所定义的毫微乳在用于护理、和/或处理头发中的美容用途。
本发明的毫微乳特别对于使皮肤、粘膜和/或头皮具有良好的增加水分的作用成为可能，并且特别适宜于处理干燥皮肤。
因此本发明的另一个论题为护理和/或使皮肤、粘膜和/或头皮增加水分的美容方法，其特征在于将如上所定义的毫微乳应用于皮肤、粘膜和/或头皮。
本发明也涉及本发明毫微乳在生产用来处理干燥皮肤的皮肤科用组合物中的用途。
最后，本发明也涉及本发明毫微乳在生产眼科用组合物中的用途。
下列实施例将使得人们能够更好的理解本发明，然而这些实施例不限定本发明。所示的量为％(重量)。实施例1：流体化妆卸妆剂(remover)油相：-Brij 72(ICI公司) 4.5％-N-硬脂酰-L-谷氨酸二钠盐(来自 0.5％Ajinomoto公司的酰基谷氨酸盐HS21)-硬脂酸异十六烷基酯(分子量＝508) 10％-十四烷酸异丙基酯(分子量＝270) 5％水相：-甘油 5％-二丙二醇 10％-水 65％
得到透明的毫微乳，该乳剂的珠滴大小为47nm，并且该乳剂的浊度为222 NTU。实施例2：用于人体的香水(scented water)油相：-Nikkol BB10(Nikko公司) 4.5％-N-硬脂酰-L-谷氨酸二钠盐(来自 0.5％Ajinomoto公司的酰基谷氨酸盐HS21)-豆油(分子量900) 8.5％-挥发性硅油(分子量＝106) 3％-香料 3％-维生素E乙酸酯 0.5％-乙醇 12.5％水相：甘油 5％水 适量至100％
得到透明的毫微乳，该乳剂的珠滴的大小为42nm，并且该乳剂的浊度为149NTU。实施例3：护发剂油相：-Compritol HD5 ATO(Gattefosse公司) 4％-二十二烷基三甲基铵氯化物 1％-鳄梨油(分子量900) 15％-乙醇 20％水相：-甘油 5％-水 适量至100％
得到透明的毫微乳，该乳剂的殊滴的大小为55nm，并且该乳剂的浊度为230NTU。
Claims (27)
1.毫微乳，它包括分散在水相中的油相并且具有小于100nm数均大小的油珠滴，其特征在于它包括在低于或等于45℃下为固体的选自乙氧化脂肪醚和乙氧化脂肪酯的表面活性剂和至少一种分子量大于400的油，且油相与表面活性剂的重量比率在2至10范围内。
2.权利要求1的毫微乳，其特征在于它具有60至600 NTU范围内的浊度。
3.权利要求1或2的毫微乳，其特征在于表面活性剂的量相对于毫微乳的总重量在0.2至15％(重量)范围内并且优选在1至8％(重量)范围内。
4.前述权利要求中任何一项的毫微乳，其特征在于油相与表面活性剂的重量比率在3至6的范围内。
5.前述权利要求中任何一项的毫微乳，其特征在于所述珠滴具有20至75nm的范围内的平均大小。
6.前述权利要求中任何一项的毫微乳，其特征在于所述表面活性剂选自由1至100个环氧乙烷单位与至少一个具有16至22个碳原子的脂肪醇链形成的醚和由1至100个环氧乙烷单位与至少一个具有16至22个碳原子的脂肪酸链形成的酯。
7.前述权利要求中任何一项的毫微乳，其特征在于所述表面活性剂选自包括5、10、20和30个环氧乙烷单位的二十二烷醇醚、包括2个环氧乙烷单位的十八烷醇醚、包括8个环氧乙烷单位的二十二烷酸酯和包括40个环氧乙烷单位的十八烷酸酯。
8.前述权利要求中任何一项的毫微乳，其特征在于所述分子量大于400的油选自动物或植物来源的油、矿物油、合成油和硅油和它们的混合物。
9.前述权利要求中任何一项的毫微乳，其特征在于所述油相另外包括至少一种分子量小于400的油。
10.前述权利要求中任何一项的毫微乳，其特征在于相对于所述油相的总重量计所述油相包括至少40％(重量)的分子量大于400的油。
11.前述权利要求中任何一项的毫微乳，其特征在于相对于所述毫微乳的总重量计所述油相的量在2至40％(重量)的范围内。
12.前述权利要求中任何一项的毫微乳，其特征在于它另外包括至少一种选自阴离子两亲性类脂、阳离子两亲性类脂和烷基磺基衍生物的离子性两亲性类脂。
13.前述权利要求的毫微乳，其特征在于所述离子性两亲性类脂选自下列物质及它们的混合物：- 联十六烷基磷酸酯和联十四烷基磷酸酯的碱性盐；- 胆固醇硫酸酯的碱性盐；- 胆固醇磷酸酯的碱性盐；- 脂氨基酸的盐(lipoamino acid)；- 磷脂酸的钠盐；- 磷脂；- 式(I)的烷基磺酸衍生物
其中R代表作为混合物或单独使用的C16-C22的烷基基团，并且M为碱金属；- 季铵盐、脂肪胺和它们的盐
14.权利要求12或13的毫微乳，其特征在于相对于所述毫微乳的总重量计所述离子两亲性类脂的量在0.01至5％(重量)的范围内。
15.前述权利要求中任何一项的毫微乳，其特征在于它包括选自低级醇、二元醇、糖类和它们的混合物的可能使该制剂的透明性得以改善的添加剂。
16.权利要求15的毫微乳，其特征在于所述添加剂以相对于所述毫微乳总重量的5至20％(重量)的范围内的浓度存在。
17.前述权利要求中任何一项的毫微乳，其特征在于它包括美容、皮肤用或眼科用活性成分。
18.局部使用的组合物，其特征在于它包括权利要求1至17的任何一项的毫微乳。
19.眼科用载体，其特征在于它包括权利要求1至17的任何一项的毫微乳。
20.药用组合物，其特征在于它包括权利要求1至17的任何一项的亳微乳。
21.权利要求1至17的任何一项的毫微乳在用于护理、处理和/或化妆皮肤、脸和/或头皮中的美容用途。
22.权利要求1至17的任何一项的毫微乳在用于护理和/或处理头发中的美容用途。
23.护理和/或使皮肤、粘膜和/或头皮增加水分的美容方法，其特征在于将权利要求1至17的任何一项的毫微乳应用于皮肤、粘膜和/或头皮上。
24.权利要求1至17的任何一项的毫微乳在生产用于处理干燥皮肤的皮肤用组合物中的用途。
25.权利要求1至17的任何一项的毫微乳在生产眼科用组合物中的用途。
26.权利要求1至17的任何一项的毫微乳的制备方法，该方法包括在10至80℃范围内在伴随剧烈搅拌下使水相与油相混合，然后在6×107Pa至18×107Pa的范围内的压力下将该混合物均化。
27.前述权利要求的方法，其特征在于所述剪切在2×106s-1至5×108s-1的范围内。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR98/16570 | 1998-12-29 | ||
| FR9816570A FR2787703B1 (fr) | 1998-12-29 | 1998-12-29 | Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1266679A true CN1266679A (zh) | 2000-09-20 |
| CN1130195C CN1130195C (zh) | 2003-12-10 |
Family
ID=9534615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN99127471A Expired - Fee Related CN1130195C (zh) | 1998-12-29 | 1999-12-28 | 基于乙氧化脂肪醚或乙氧化脂肪酯的毫微乳及其用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6375960B1 (zh) |
| EP (1) | EP1016453B2 (zh) |
| JP (2) | JP3913951B2 (zh) |
| KR (1) | KR100345097B1 (zh) |
| CN (1) | CN1130195C (zh) |
| AT (1) | ATE205111T1 (zh) |
| BR (1) | BR9906206A (zh) |
| CA (1) | CA2293177A1 (zh) |
| DE (1) | DE69900264T3 (zh) |
| ES (1) | ES2163926T5 (zh) |
| FR (1) | FR2787703B1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113423494A (zh) * | 2019-02-13 | 2021-09-21 | 花王株式会社 | 表面活性剂组合物 |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2787027B1 (fr) * | 1998-12-14 | 2001-01-12 | Oreal | Nanoemulsion a base d'esters gras de sucre ou d'ethers gras de sucre et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| FR2787703B1 (fr) * | 1998-12-29 | 2001-01-26 | Oreal | Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| JP2001303020A (ja) * | 2000-04-24 | 2001-10-31 | Sunstar Inc | 透明液状組成物 |
| US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
| FR2811564B1 (fr) | 2000-07-13 | 2002-12-27 | Oreal | Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique |
| FR2819427B1 (fr) | 2001-01-18 | 2003-04-11 | Oreal | Nanoemulsion translucide, son procede de fabrication et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| US20030165545A1 (en) * | 2002-01-30 | 2003-09-04 | Allergan, Inc. | Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same |
| WO2004037225A2 (en) | 2002-10-25 | 2004-05-06 | Foamix Ltd. | Cosmetic and pharmaceutical foam |
| IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
| US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
| US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
| US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
| US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
| US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
| US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
| US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
| US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
| US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
| US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
| US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
| US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
| US20050089541A1 (en) * | 2003-10-23 | 2005-04-28 | L'oreal | Chlorhexidine-containing O/W emulsion |
| PE20050596A1 (es) * | 2003-12-19 | 2005-10-18 | Novartis Ag | Microemulsion que comprende un inhibidor renina |
| DE102004008107A1 (de) * | 2004-02-18 | 2005-09-08 | Cognis Deutschland Gmbh & Co. Kg | Mikroemulsionen |
| FR2881955B1 (fr) | 2005-02-11 | 2007-05-11 | Oreal | Nanoemulsion cosmetique contenant un compose d'uree hydroxyle |
| CA2600054A1 (en) * | 2005-03-09 | 2006-09-21 | Combe Incorporated | Stable mixed emulsions |
| FR2885797B1 (fr) * | 2005-05-17 | 2007-07-27 | Oreal | Particules d'huile gelifiee comportant au moins un filtre solaire hydrophobe |
| US20060263438A1 (en) * | 2005-05-17 | 2006-11-23 | L'oreal | Gelled oil particles for targeting sebaceous glands and/or hair follicles |
| FR2885808B1 (fr) | 2005-05-19 | 2007-07-06 | Oreal | Vectorisation de dsrna par des particules cationiques et utilisation topique. |
| TWI402034B (zh) * | 2005-07-28 | 2013-07-21 | Dow Agrosciences Llc | 具有被層狀液晶覆膜包覆之油球之水包油乳化劑之農用組成物 |
| US20070042007A1 (en) * | 2005-08-19 | 2007-02-22 | Joseph Schwarz | Topical composition for delivery of salicylate esters |
| WO2007040598A2 (en) * | 2005-09-19 | 2007-04-12 | Combe Incorporated | Stable emulsion systems with high salt tolerance |
| FR2907012B1 (fr) | 2006-10-12 | 2012-09-21 | Galderma Sa | Composition dermatologique comprenant des nanocapsules d'avermectine, son procede de preparation et son utilisation |
| US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
| GB0623838D0 (en) * | 2006-11-29 | 2007-01-10 | Malvern Cosmeceutics Ltd | Novel compositions |
| EP1938801A1 (en) * | 2006-12-22 | 2008-07-02 | Biofrontera Bioscience GmbH | Nanoemulsion |
| US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| FR2924020B1 (fr) * | 2007-11-26 | 2009-11-20 | Oreal | Emulsion cosmetique ou dermatologique a base d'ethers gras ethoxyles, d'esters gras ethoxyles et/ou d'esters gras de glycerol et de filtres uv organiques lipophiles;procede de fabrication et utilisations |
| CN101909654A (zh) * | 2007-11-28 | 2010-12-08 | 联邦科学和工业研究组织 | 纳米乳剂 |
| WO2009069006A2 (en) | 2007-11-30 | 2009-06-04 | Foamix Ltd. | Foam containing benzoyl peroxide |
| WO2009072007A2 (en) | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
| WO2010041141A2 (en) | 2008-10-07 | 2010-04-15 | Foamix Ltd. | Oil-based foamable carriers and formulations |
| WO2009090558A2 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
| WO2009100144A1 (en) * | 2008-02-04 | 2009-08-13 | Dow Agrosciences Llc | Stabilized oil-in-water emulsions including meptyl dinocap |
| US9185905B2 (en) * | 2008-03-07 | 2015-11-17 | Dow Agrosciences Llc | Stabilized oil-in-water emulsions including agriculturally active ingredients |
| WO2009145959A1 (en) * | 2008-03-07 | 2009-12-03 | University Of Toledo | High throughput carbon nanotube growth system, and carbon nanotubes and carbon nanofibers formed thereby |
| PT2271212T (pt) * | 2008-03-07 | 2017-12-06 | Dow Agrosciences Llc | Emulsões óleo-em-água estabilizadas incluíndo ingredientes activos para agricultura |
| FR2938191B1 (fr) | 2008-11-07 | 2011-01-14 | Oreal | Emulsion huile-dans-eau contenant un polymere amphiphile et un elastomere silicone |
| FR2940109B1 (fr) * | 2008-12-18 | 2011-02-11 | Natura Cosmeticos Sa | Nanoemulsion huile dans l'eau contenant de l'huile de noix du bresil, composition cosmetique et produit cosmetique renfermant cette emulsion et utilisation de cette derniere. |
| ES2626327T3 (es) | 2009-02-06 | 2017-07-24 | The Regents Of The University Of California | Agentes enlazantes de calcio que inducen crecimiento del cabello y/o crecimiento de las uñas |
| WO2010125470A2 (en) | 2009-04-28 | 2010-11-04 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
| CA2769677A1 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
| CA2769625C (en) | 2009-07-29 | 2017-04-11 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
| WO2011064631A1 (en) | 2009-10-02 | 2011-06-03 | Foamix Ltd. | Surfactant-free, water-free, foamable compositions and breakable foams and their uses |
| US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
| US8174881B2 (en) | 2009-11-24 | 2012-05-08 | Micron Technology, Inc. | Techniques for reducing disturbance in a semiconductor device |
| US20110229516A1 (en) * | 2010-03-18 | 2011-09-22 | The Clorox Company | Adjuvant phase inversion concentrated nanoemulsion compositions |
| DE102010021688A1 (de) | 2010-05-27 | 2011-12-01 | Qineva Gmbh & Co. Kg | Verfahren zur Herstellung eines micellaren Wirkstoffkonzentrats |
| JP5584524B2 (ja) * | 2010-06-07 | 2014-09-03 | 花王株式会社 | 水中油型乳化組成物及びその製造方法 |
| DE102010056192A1 (de) | 2010-12-28 | 2012-06-28 | Gabriele Blume | Kolloidales Trägersystem mit penetrierenden Eigenschaften zum Einschließen lipophiler Wirkstoffe und Öle für die topische Anwendung |
| BR112013017674B8 (pt) | 2011-01-14 | 2022-06-28 | Dow Agrosciences Llc | Composição em emulsão óleo-em-água apresentando pelo menos um composto agricolamente ativo, e método para tratamento de uma planta |
| JP5360847B2 (ja) * | 2011-09-27 | 2013-12-04 | 株式会社 資生堂 | 透明な水中油型乳化化粧料 |
| DK2827711T3 (da) | 2012-03-19 | 2019-09-23 | Buck Inst Res Aging | App-specifikke bace-inhibitorer (asbi'er) og anvendelse deraf |
| FR2998793B1 (fr) | 2012-11-30 | 2014-11-28 | Oreal | Composition cosmetique sous forme d'emulsion huile-dans-eau |
| KR20150102058A (ko) * | 2012-12-31 | 2015-09-04 | 제이알엑스 바이오테크놀로지, 인코포레이티드 | 액체 국소 제약 나노-에멀젼 제제 |
| US10202355B2 (en) | 2013-02-12 | 2019-02-12 | Buck Institute For Research On Aging | Hydantoins that modulate bace-mediated app processing |
| EP2978409B1 (en) * | 2013-03-27 | 2018-01-10 | Comprehensive Drug Enterprises Ltd | Ophthalmic composition, method for preparing the same, and use of the same |
| FR3015870B1 (fr) | 2013-12-27 | 2016-02-05 | Oreal | Dispositif pour le maquillage par transfert des matieres keratiniques. |
| MX2020012139A (es) | 2016-09-08 | 2021-01-29 | Vyne Pharmaceuticals Inc | Composiciones y metodos para tratar rosacea y acne. |
| US11186622B2 (en) | 2017-01-05 | 2021-11-30 | The Regents Of The University Of California | PAC1 receptor agonists (MAXCAPS) and uses thereof |
| GB2584009B (en) | 2017-08-28 | 2022-03-23 | Revagenix Inc | Aminoglycosides and uses thereof |
| KR102692643B1 (ko) | 2017-11-10 | 2024-08-06 | (주)아모레퍼시픽 | 바이겔 타입의 화장료 조성물 |
| FR3076213B1 (fr) * | 2017-12-29 | 2020-01-17 | L'oreal | Composition sous forme de nanoemulsion huile-dans-eau comprenant au moins un tensioactif cationique, au moins un polyol, une faible teneur en eau, et au moins un corps gras |
| US11673907B2 (en) | 2018-04-03 | 2023-06-13 | Revagenix, Inc. | Modular synthesis of aminoglycosides |
| EP3914245A4 (en) | 2019-01-22 | 2022-08-24 | Aeovian Pharmaceuticals, Inc. | MTORC MODULATORS AND THEIR USES |
| IL315304A (en) | 2022-03-04 | 2024-10-01 | Revagenix Inc | Broad-spectrum aminoglycoside antibiotics and their uses |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4146499A (en) * | 1976-09-18 | 1979-03-27 | Rosano Henri L | Method for preparing microemulsions |
| US4083974A (en) * | 1977-03-07 | 1978-04-11 | The Upjohn Company | Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether |
| US4496473A (en) * | 1982-04-27 | 1985-01-29 | Interox Chemicals Limited | Hydrogen peroxide compositions |
| GB8519426D0 (en) * | 1985-08-01 | 1985-09-04 | Ici Plc | Composition for personal care products |
| US4797272A (en) * | 1985-11-15 | 1989-01-10 | Eli Lilly And Company | Water-in-oil microemulsions for cosmetic uses |
| JPH0657316B2 (ja) * | 1986-11-18 | 1994-08-03 | 株式会社資生堂 | マイクロエマルシヨン |
| JP2785981B2 (ja) | 1989-11-20 | 1998-08-13 | 株式会社資生堂 | 乳化組成物 |
| DE4039063A1 (de) * | 1990-12-07 | 1992-06-11 | Wella Ag | Haarkurmittel in form einer mikroemulsion |
| FR2725369B1 (fr) * | 1994-10-07 | 1997-01-03 | Oreal | Composition cosmetique ou dermatologique constituee d'une emulsion huile dans eau a base de globules huileux pourvus d'un enrobage cristal liquide lamellaire |
| ATE231410T1 (de) * | 1994-11-04 | 2003-02-15 | Croda Inc | Emulgiermittelzusammensetzungen auf basis von fettalkohol- phosphatestern |
| FR2730932B1 (fr) † | 1995-02-27 | 1997-04-04 | Oreal | Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie |
| DE19509079A1 (de) † | 1995-03-15 | 1996-09-19 | Beiersdorf Ag | Kosmetische oder dermatologische Mikroemulsionen |
| FR2742676B1 (fr) * | 1995-12-21 | 1998-02-06 | Oreal | Nanoemulsion transparente a base de tensioactifs silicones et utilisation en cosmetique ou en dermopharmacie |
| FR2745716B1 (fr) * | 1996-03-07 | 1998-04-17 | Oreal | Emulsions huile-dans-eau moussantes pressurisables ultrafines |
| DE19622613C2 (de) † | 1996-06-05 | 1998-04-16 | Henkel Kgaa | Kosmetische und/oder pharmazeutische Emulsionen |
| US5871762A (en) * | 1996-10-07 | 1999-02-16 | The Procter & Gamble Company | Cosmetic applicators which contain stable oil-in-water emulsions |
| FR2755854B1 (fr) * | 1996-11-15 | 1998-12-24 | Oreal | Nanoemulsion a base de lipides amphiphiles non-ioniques et cationiques et utilisations |
| ATE240088T1 (de) * | 1996-12-13 | 2003-05-15 | Vesifact Ag | Kosmetische präparate in form einer nanodispersion |
| FR2760970B1 (fr) * | 1997-03-18 | 2000-03-10 | Oreal | Nanoemulsions a base de lipides amphiphiles non-ioniques et de silicones aminees et utilisations |
| JPH1121587A (ja) * | 1997-07-07 | 1999-01-26 | Toshiba Silicone Co Ltd | シリコーンエマルジョン組成物、製造方法および化粧料 |
| FR2787703B1 (fr) * | 1998-12-29 | 2001-01-26 | Oreal | Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
-
1998
- 1998-12-29 FR FR9816570A patent/FR2787703B1/fr not_active Expired - Fee Related
-
1999
- 1999-11-17 DE DE69900264T patent/DE69900264T3/de not_active Expired - Lifetime
- 1999-11-17 ES ES99402855T patent/ES2163926T5/es not_active Expired - Lifetime
- 1999-11-17 AT AT99402855T patent/ATE205111T1/de not_active IP Right Cessation
- 1999-11-17 EP EP99402855A patent/EP1016453B2/fr not_active Expired - Lifetime
- 1999-12-10 BR BR9906206-2A patent/BR9906206A/pt not_active IP Right Cessation
- 1999-12-14 KR KR1019990057463A patent/KR100345097B1/ko not_active IP Right Cessation
- 1999-12-21 CA CA002293177A patent/CA2293177A1/fr not_active Abandoned
- 1999-12-27 JP JP37172099A patent/JP3913951B2/ja not_active Expired - Lifetime
- 1999-12-28 CN CN99127471A patent/CN1130195C/zh not_active Expired - Fee Related
- 1999-12-29 US US09/474,074 patent/US6375960B1/en not_active Expired - Lifetime
-
2005
- 2005-03-08 JP JP2005064349A patent/JP2005187483A/ja not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113423494A (zh) * | 2019-02-13 | 2021-09-21 | 花王株式会社 | 表面活性剂组合物 |
| CN113423494B (zh) * | 2019-02-13 | 2023-06-20 | 花王株式会社 | 表面活性剂组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20000052471A (ko) | 2000-08-25 |
| DE69900264T2 (de) | 2002-04-18 |
| ATE205111T1 (de) | 2001-09-15 |
| FR2787703A1 (fr) | 2000-06-30 |
| BR9906206A (pt) | 2001-02-06 |
| ES2163926T3 (es) | 2002-02-01 |
| DE69900264D1 (de) | 2001-10-11 |
| DE69900264T3 (de) | 2008-04-17 |
| FR2787703B1 (fr) | 2001-01-26 |
| ES2163926T5 (es) | 2008-04-01 |
| JP2005187483A (ja) | 2005-07-14 |
| EP1016453A1 (fr) | 2000-07-05 |
| CN1130195C (zh) | 2003-12-10 |
| US6375960B1 (en) | 2002-04-23 |
| EP1016453B1 (fr) | 2001-09-05 |
| KR100345097B1 (ko) | 2002-07-24 |
| JP3913951B2 (ja) | 2007-05-09 |
| CA2293177A1 (fr) | 2000-06-29 |
| EP1016453B2 (fr) | 2007-10-10 |
| JP2000191503A (ja) | 2000-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1130195C (zh) | 基于乙氧化脂肪醚或乙氧化脂肪酯的毫微乳及其用途 | |
| CN1119984C (zh) | 基于脱水山梨糖醇脂肪酸酯的毫微乳液及其应用 | |
| US6464990B2 (en) | Nanoemulsion based on ethylene oxide and propylene oxide block copolymers and its uses in the cosmetics, dermatological and/or ophthalmological fields | |
| US6541018B1 (en) | Nanoemulsion based on glycerol fatty esters, and its uses in the cosmetics, dermatological and/or ophthalmological fields | |
| JP3545299B2 (ja) | アルキルエーテルクエン酸エステルベースのナノエマルジョン、及び化粧料、皮膚科学、薬学及び／又は眼科学分野におけるその使用 | |
| KR100369259B1 (ko) | 당 지방 에스테르 또는 당 지방 에테르를 기재로 한나노에멀션, 및 화장품, 피부학 및/또는 안과학분야에서의 그의 용도 | |
| US6461625B1 (en) | Nanoemulsion based on alkoxylated alkenyl succinates or alkoxylated alkenyl succinates of glucose and its uses in the cosmetics, dermatological, opthalmological and/or pharmaceutical fields | |
| JP2000178129A (ja) | 脂肪酸または脂肪アルコ―ル、カルボン酸及びグリセロ―ルの混合エステルに基づくナノエマルション及びその化粧、皮膚科及び／または眼科分野における使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |